EP0000741A2 - Indolacetoxyacetylaminoacid derivatives, process for their preparation and their use in drugs - Google Patents

Indolacetoxyacetylaminoacid derivatives, process for their preparation and their use in drugs Download PDF

Info

Publication number
EP0000741A2
EP0000741A2 EP7878100523A EP78100523A EP0000741A2 EP 0000741 A2 EP0000741 A2 EP 0000741A2 EP 7878100523 A EP7878100523 A EP 7878100523A EP 78100523 A EP78100523 A EP 78100523A EP 0000741 A2 EP0000741 A2 EP 0000741A2
Authority
EP
European Patent Office
Prior art keywords
group
ace
optionally substituted
general formula
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP7878100523A
Other languages
German (de)
French (fr)
Other versions
EP0000741B1 (en
EP0000741A3 (en
Inventor
Karl-Heinz Dr. Boltze
Hans-Dieter Dr. Dell
Haireddin Dr. Jacobi
Wolfgang Dr. Opitz
Günter Schöllnhammer
Dieter Dr. Vollbrecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Troponwerke GmbH
Original Assignee
Troponwerke GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Troponwerke GmbH filed Critical Troponwerke GmbH
Publication of EP0000741A2 publication Critical patent/EP0000741A2/en
Publication of EP0000741A3 publication Critical patent/EP0000741A3/en
Application granted granted Critical
Publication of EP0000741B1 publication Critical patent/EP0000741B1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Definitions

  • the present invention relates to new indolacetoxyacetylamino acid derivatives, processes for their preparation and their use as medicaments, in particular as anti-inflammatories and anti-inflammatory drugs.
  • an optionally substituted alkyl group for R 1 to R 3 preferably denotes a straight-chain or branched-chain alkyl group having up to 5 carbon atoms.
  • Examples include the methyl, ethyl, propyl, isopropyl, butyl and isobutyl groups, especially the methyl, ethyl and isobutyl group.
  • halogen atoms in particular by chlorine, bromine, fluorine, hydroxyl, mercapto, alkoxy or alkylthio groups, amino groups, acylamino groups, carboxyl groups and nitro groups, the alkyl, alkoxy and acyl groups mentioned up to 4 C - Contain atoms, in particular hydroxyl, amino, marcapto, methoxy and methyl mercapto groups.
  • An optionally substituted aralkyl group for R 1 to R 3 preferably denotes the benzyl group, phenylethyl group or phenylisopropyl group, in particular the benzyl group; it can be substituted by 1 to 2 hydroxyl groups, lower alkoxy groups having 1 to 4 carbon atoms, nitro groups, halogen atoms, preferably by a hydroxyl group.
  • An optionally substituted Heterocyclusmethyl administrat for R 1 to R 3 is preferably a thenyl, Pyrrolmethyl-, -pyrrolidinylmethyl-, P iperidinmethyl-, Indolmethyl-, imidazolemethyl-, Chinolinmethyl distr, in particular the Indolylnethyl distr and Imidazolmethyl distr; it can be substituted, preferably by halogen atoms, lower alkyl or alkoxy groups having 1 to 4 carbon atoms or nitro groups.
  • An optionally substituted amino group for R 1 is preferably an acylamino group, in particular a lower alkoxycarbonyl group with up to 5 carbon atoms or a benzyloxycarbonyl group.
  • An optionally substituted aryl group for R 1 to R 3 preferably denotes a phenyl or naphthyl group which is optionally monosubstituted to trisubstituted by halogen atoms, hydroxyl groups, alkoxy groups having up to 4 carbon atoms, nitro groups, trifluoromethyl groups and / or lower alkyl groups having up to 4 carbon atoms is.
  • An optionally substituted alkoxy group for R 4 preferably represents an alkoxy group having 1 to 4 carbon atoms, in particular a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl or tertiary butyloxy group, which in turn can be mono- to trisubstituted by halogen atoms, hydroxyl groups and / or alkoxy groups having up to 4 carbon atoms.
  • An optionally substituted aralkoxy group for R 4 means in particular the benzyl, phenylethyl, phenylpropyl, phenylisopropyloxy group, preferably the benzyloxy group; it can be substituted by 1 to 2 halogen atoms or alkoxy groups having 1 to 2 carbon atoms.
  • An optionally substituted arylamino group for R 4 preferably denotes the phenylamino group, which can be substituted by halogen atoms, alkyl or alkoxy groups having 1 to 4 carbon atoms or by a trifluoromethyl group.
  • An optionally substituted aralkylamino group for R 4 is in particular a benzyl, phenylethyl, phenylpropyl or phenylisopropylamino group, which can also be substituted as described above for the arylamino group.
  • physiologically compatible addition salts can be formed with organic and inorganic bases.
  • salts are preferably sodium salts, potassium, magnesium, ammonium, methylammonium, dimethylammonium salts or the 2-hydroxyethylammonium salt.
  • addition salts which are physiologically compatible can also be formed with acids.
  • salts are halides, preferably chlorides, sulfates, citrates, tartrates, maleinates and sulfonates.
  • the compounds of general formula (I) according to the invention show a more advantageous active ingredient than the indomethacinserine derivatives of DOS 2 413 125 known from the prior art.
  • the compounds according to the invention thus represent an enrichment of pharmacy.
  • reaction sequence of variant a) can be represented by the following formula:
  • chloroformic acid esters of the general formula (II) which can be used as starting compounds are known and the ACE-OH used as starting compound is also known (DOS 2 234 651).
  • the mixed anhydrides of the general formula (III) formed as an intermediate are new, but cannot be identified because, like the majority of the mixed anhydrides known in the literature, they decompose during processing (cf.Houben-Weyl, Methods of Organic Chemistry , 4th edition, volume 15/2, page 17, 3rd paragraph).
  • diluents inert organic solvents are suitable as diluents, in particular those which are polar aprotic. Examples include tetrahydrofuan, dioxane, dimethylformamide, hexamethylphosphoric triamide.
  • the reaction is conveniently carried out in the presence of acid binders.
  • acid binders All customary agents which are able to bind the hydrogen chloride released can be used as the acid binder. These preferably include alkali hydroxides and carbonates or organic bases such as pyridine and triethylarin.
  • reaction temperatures are expediently below 0 ° C., since otherwise racemizations occur; they can be varied within a certain range. In general, mar works at temperatures between O o to -25 o C, preferably between -10 ° and -20 ° C.
  • the reaction is usually carried out at normal pressure.
  • the reaction time is between 6 and 24 hours, preferably 14 to 20 hours.
  • Working up is preferably carried out by evaporation in vacuo, taking up in one of the customary organic solvents, neutral washing, optionally cleaning on silica gel and recrystallization.
  • reaction scheme If an activated ester of the general formula (V) is used for the reaction instead of a mixed anhydride of ACE-OH, the reaction of variant b) can be represented by the following reaction scheme:
  • the compounds of the general formula (V) used as reactants are not yet known, but can be known in a manner known per se by reacting 1 mol of ACE-OH and 1 M cl of the correspondingly substituted phenol in a polar aprotic organic solvent, such as, for example, tetrahydrofuran. in the presence of 1 mole of a carbodiimide, such as D icyclohexycarbodiimid or carbonyldiimidazole are obtained in approximately 1 1/2 hours of reaction at room temperature.
  • a polar aprotic organic solvent such as, for example, tetrahydrofuran.
  • Process (V) ⁇ (I) according to the invention is advantageously carried out in the presence of diluents.
  • Suitable diluents are the organic solvents known for this reaction, preferably dimethylformamide, dioxane, pyridine or mixtures thereof with water.
  • addition salts of (IV) are used for reactions, the process is advantageously carried out in the presence of acid binders.
  • acid binders include alkali metal hydroxides, carbonates or strong organic anines, preferably triethylamine.
  • the reaction temperatures can be varied within a certain range. Normally one works at 15-25 ° C, since the reaction times are extended disproportionately at lower temperatures, but the formation of racemates is promoted at higher temperatures. A certain racemate formation cannot be ruled out even in the reaction at room temperature.
  • the process is usually carried out at normal pressure.
  • 1 xol of the amino acid derivative (IV) is preferably used per mole of the activated ester (V).
  • the working up is expediently carried out by diluting the mixture with water, taking it up in a suitable organic solvent, neutralizing, evaporating and recrystallizing from suitable solvents.
  • the serine derivatives of the general formula (VI) used as starting compounds are known.
  • the reaction is preferably carried out in the presence of diluents.
  • Polar aprotic organic solvents can be used as diluents. Examples include tetrahydrofuran, dioxane, dimethylformamide, hexamethylphosphoric triamide.
  • the reaction according to the invention is preferably carried out in the presence of a dehydrating agent. Examples include dicyclohexylcarbodiinide or carbonyldiimidazole in the presence of catalytic amounts of a basic catalyst, preferably sodium hydride.
  • reaction temperatures can be varied over a wide range; Usually one works between 10 and 40 ° C, preferably between 15 and 25 ° C.
  • 1 mol of the ACE-OH is first reacted with 1 mol of carbonyldiimidazole and 1 mol of the amino acid derivative is only added after the CO 2 evolution has ended.
  • Working up is carried out in the usual way, preferably by evaporation in vacuo, taking up in a suitable solvent and cleaning on silica gel.
  • the amino protective group R 6 is cleaved off according to the methods known from the literature in peptide chemistry.
  • the new active compounds can be converted in a known manner into the customary formulations, such as tablets, capsules, dragees, pills, granules, aerosols, syrups, emulsions, suspensions, solutions, ointments, gels, creams, jellies, using inert, non-toxic; pharmaceutically acceptable carriers or solvents.
  • the therapeutically active compound should be present in a concentration of about 0.5 to 90% by weight of the total mixture, i.e. in amounts sufficient to achieve the dosage range indicated.
  • the formulations are prepared, for example, by pre-stretching the active ingredients with solvents and / or carriers, optionally using emulsifiers and / or dispersants, e.g. if water is used as a diluent, organic solvents can optionally be used as auxiliary solvents.
  • the application takes place in the usual way, preferably orally or parenterally, lckally, intramuscularly or intravenously.
  • tablets in addition to the carrier substances mentioned, can also contain additives such as sodium citrate, calcium carbomate and dicalcium phosphate, together with various additives such as starch, preferably potato starch, gelatin and the like. Glidants such as magnesium stearate, sodium lauryl sulfate and talc can also be used for tableting.
  • aqueous suspensions and / or. ' Elixirs which are intended for oral applications, can be mixed with various flavor enhancers or colorants in addition to the additives mentioned.
  • solutions of the active ingredients can be used using suitable liquid carrier materials.
  • the dosage is about 10 up to 200, especially 30 to 80 mg per dose.
  • a suspension of 0.005 mol of phenylalanyl tyrosine methyl ester trifluoroacetate in 15 ml absolute dimethylformamide is initially mixed with stirring at 0 ° C. with 0.005 mol of triethylamine and after 10 minutes with 0.005 mol of ACE-2,4,5-trichlorophenyl ester. After stirring for two hours, finally at room temperature, the reaction mixture is mixed with 150 ml of water, extracted three times with xthylacetate and the organic phase is extracted three times with nHCl solution. The solution is then washed neutral with water, dried over Na 2 SO 4 and evaporated.
  • N ⁇ -Forryl-N ⁇ -benzyloxycarbonyldiaminobutyrylphenylahanyl phenylalanimethyl
  • N ⁇ -ACE-N ⁇ -Benznloxvcarbonyldiaminobutyrylphenylalany1 phenylalanine methyl ester

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Indolylacetoxyacetylaminoacetic acid derivatives of the general formula (I) see diagramm : EP0000741,P17,F3 in which m and n represent the numbers 0 or 1, X represents a -NH- or -OCH2 - group, R1 , R2 and R3 are identical or different and each represent hydrogen, an alkyl with 1 to 5 carbon atoms optionally substituted by hydroxy, alkoxy with 1 to 4 carbon atoms, alkylthio with 1 to 4 carbon atoms or by phenylalkoxycarbonylamino with 1 to 4 carbon atoms in the alkyl part, or represents a phenyl or phenylalkyl group with 1 to 4 carbon atoms in the alkyl part, the phenyl rings optionally being substituted by trifluoromethyl, alkoxy with 1 to 4 carbon atoms, hydroxy or halogen or represents a heterocyclic methyl group with 5 to 6 ring members, in which 1 or 2 members can be replaced by nitrogen and to which a benzene ring is optionally fused, or in the case where m and n each represent 0, R1 additionally represents an amino group, an alkoxycarbonylamino group or a phenylalkoxycarbonylamino group with in each case 1 to 5 carbon atoms in the alkoxy part, R4 represents hydroxy, alkoxy with 1 to 4 carbon atoms, phenalkoxy with 1 to 4 carbon atoms in the alkoxy part, amino, alkylamino with 1 to 4 carbon atoms in the alkyl part, benzylamino or phenylamino, and their physiologically acceptable salts appropriately formed with acids and bases.

Description

Die vorliegende Erfindung betrifft neue Indolacetoxyacetylaminosäurederivate, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel, insbesondere als Entzündungshemmer und Antirheumatika.The present invention relates to new indolacetoxyacetylamino acid derivatives, processes for their preparation and their use as medicaments, in particular as anti-inflammatories and anti-inflammatory drugs.

Die Erfindung betrifft neue Indolylacetoxyacetylaminoessigsäurederivate der allgemeinen Formel .

Figure imgb0001
in welcher

  • m und n für die Ziffern O oder 1 stehen,
  • X für eine -NH- oder -OCH2-Gruppe steht,
  • R1,R2 und R3 gleich oder verschieden sein können und für ein Wasserstoffatom, eine gegebenenfalls substituierte Alkylgruppe, eine gegebenenfalls substituierte Arylgruppe, eine gegebenenfalls substituierte Aralkylgruppe, eine gegebenenfalls substituierte Heterocyclusmethylgruppe mit 1 oder 2 Ringen und mit je 5, 6 oder 7 Ringgliedern, in denen 1 oder 2 Glieder durch Heteroatome ersetzt sein können, und für den Fall, daß m und n für die Ziffer O stehen,
  • R1 für eine Aminogruppe, eine Alkoxycarbonylgruppe oder eine Aralkoxycarbonylgruppe steht,
  • R4 für eine Hydroxygruppe oder für eine gegebenenfalls substituierte Alkoxygruppe, eine gegebenenfalls substituierte Aralkoxygruppe, eine Aminogruppe oder eine gegebenenfalls substituierte Alkylaminogruppe, eine gegebenenfalls substituierte Aralkylaminogruppe, eine gegebenenfalls substituierte Arylaminogruppe steht,
    sowie deren gegebenenfalls mit Säuren und Basen gebildeten physiologisch verträglichen Salze.
The invention relates to new indolylacetoxyacetylaminoacetic acid derivatives of the general formula.
Figure imgb0001
 in which
  • m and n stand for the digits O or 1,
  • X represents an -NH or -OCH 2 group,
  • R 1 , R 2 and R 3 may be the same or different and represent a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted aralkyl group, an optionally substituted heterocycle methyl group with 1 or 2 rings and each with 5, 6 or 7 Ring members in which 1 or 2 members can be replaced by heteroatoms, and in the event that m and n stand for the number O,
  • R 1 represents an amino group, an alkoxycarbonyl group or an aralkoxycarbonyl group,
  • R 4 represents a hydroxyl group or an optionally substituted alkoxy group, an optionally substituted aralkoxy group, an amino group or an optionally substituted alkylamino group, an optionally substituted aralkylamino group, an optionally substituted arylamino group,
    as well as their physiologically tolerable salts which may be formed with acids and bases.

Es wurde gefunden, daß man die erfindungsgemäßen Verbindungen der allgemeinen Formel (I), in welcher X, m, n und R1 bis R4 die oben angeführte Bedeutung haben, erhält, wenn man

  • a) [1-(4-Chlorbenzoyl)-5-methoxy-2-methyl-3-indoly1]acetoxy- essigsäure (nachfolgend als ACE-OH bezeichnet) mit Chlorameisensäureestern der allgemeinen Formel
    Figure imgb0002
    in welcher
    • R5 für eine Alkylgruppe steht, zu gemischten Anhydriden der allgemeinen Formel
      Figure imgb0003
      in welcher
    • R5 die oben angegebene Bedeutung hat, umsetzt und diese mit Verbindungen der allgemeinen Formel
      Figure imgb0004
      in welcher
    • m, n, R1 bis R4 die oben angeführte Bedeutung haben, zur Reaktion bringt

    oder
  • b) die Verbindung ACE-OH mit einem entsprechend substituierten Phenol zu einem aktivierten Ester der allgemeinen Formel
    Figure imgb0005
    in welcher
    • Y für 2 bis 5 Halogenatome, 1 bis 2 Nitrogruppen oder für mehrere andere Elektronen-anziehende Gruppen steht,

    kondensiert und mit Verbindungen der allgemeinen Formel (IV), in welcher m, n, R1 bis R4 die oben angeführte Bedeutung haben, umsetzt
    oder
  • c) für den Fall, daß Hydroxylgruppen enthaltende Aminosäurederivate esterartig verknüpft werden sollen, die Verbindung ACE-OH mit Verbindungen der allgemeinen Formel
    Figure imgb0006
    in welcher
    • R4 die oben angeführte Bedeutung hat und
    • R6 für eine in der Peptidchemie übliche Aminoschutzgruppe, beispielsweise für eine Alkoxycarbonyl-oder eine Aralkoxycarbonylgruppe steht, umsetzt und anschließend den Rest R4 in bekannter Weise abspaltet

und gegebenenfalls die so erhaltenen Verbindungen der allgemeinen Formel (I) mit Säuren und Basen in die physiologisch verträglichen Salze verwandelt.It has been found that the compounds of the general formula (I) according to the invention in which X, m, n and R 1 to R 4 have the meaning given above are obtained if
  • a) [1- (4-Chlorobenzoyl) -5-methoxy-2-methyl-3-indoly1] acetoxyacetic acid (hereinafter referred to as ACE-OH) with chloroformic acid esters of the general formula
    Figure imgb0002
     in which
    • R 5 represents an alkyl group, to mixed anhydrides of the general formula
      Figure imgb0003
       in which
    • R 5 has the meaning given above, and this with compounds of the general formula
      Figure imgb0004
       in which
    • m, n, R 1 to R 4 have the meaning given above, brings about the reaction

    or
  • b) the compound ACE-OH with a correspondingly substituted phenol to an activated ester of the general formula
    Figure imgb0005
     in which
    • Y represents 2 to 5 halogen atoms, 1 to 2 nitro groups or for several other electron-attracting groups,

    condensed and reacted with compounds of the general formula (IV) in which m, n, R 1 to R 4 have the meaning given above
    or
  • c) in the event that amino acid derivatives containing hydroxyl groups are to be linked in an ester-like manner, the compound ACE-OH with compounds of the general formula
    Figure imgb0006
     in which
    • R 4 has the meaning given above and
    • R 6 is an amino protective group which is customary in peptide chemistry, for example an alkoxycarbonyl or an aralkoxycarbonyl group, and then the radical R 4 is split off in a known manner

and optionally the compounds of the general formula (I) thus obtained are converted into the physiologically tolerable salts with acids and bases.

In der allgemeinen Formel (I) bedeutet eine gegebenenfalls substituierte Alkylgruppe für R, bis R3 vorzugsweise eine gerade- oder verzweigtkettige Alkylgruppe mit bis zu 5 C-Atomen. Beispielhaft seien genannt die Methyl-, Äthyl-, Propyl-, Isopropyl-, Butyl- und Isobutylgruppen, insbesondere die Methyl-, Äthyl- und Isobutylgruppe. Sie ist vorzugsweise substituiert durch Halogenatome, insbesondere durch Chlor, Brom, Fluor, Hydroxy-, Mercapto-, Alkoxy- bzw. Alkylthiogruppen, Aminogruppen, Acylaminogruppen, Carboxylgruppen und Nitrogruppen, wobei die genannten Alkyl-, Alkoxy- und Acylgruppen bis zu 4 C-Atome enthalten, insbesondere Hydroxy-, Amino-, Marcapto-, Methoxy-und Methylmercaptogruppen.In the general formula (I), an optionally substituted alkyl group for R 1 to R 3 preferably denotes a straight-chain or branched-chain alkyl group having up to 5 carbon atoms. Examples include the methyl, ethyl, propyl, isopropyl, butyl and isobutyl groups, especially the methyl, ethyl and isobutyl group. It is preferably substituted by halogen atoms, in particular by chlorine, bromine, fluorine, hydroxyl, mercapto, alkoxy or alkylthio groups, amino groups, acylamino groups, carboxyl groups and nitro groups, the alkyl, alkoxy and acyl groups mentioned up to 4 C - Contain atoms, in particular hydroxyl, amino, marcapto, methoxy and methyl mercapto groups.

Eine gegebenenfalls substituierte Aralkylgruppe für R1 bis R3 bedeutet vorzugsweise die Benzylgruppe, Phenyläthylgruppe oder Phenylisopropylgruppe, insbesondere die Benzylgruppe; sie kann substituiert sein durch 1 bis 2 Hydroxygruppen, niedere Alkoxygruppen mit 1 bis 4 C-Atomen, Nitrogruppen, Halogenatome, vorzugsweise durch eine Hydroxygruppe.An optionally substituted aralkyl group for R 1 to R 3 preferably denotes the benzyl group, phenylethyl group or phenylisopropyl group, in particular the benzyl group; it can be substituted by 1 to 2 hydroxyl groups, lower alkoxy groups having 1 to 4 carbon atoms, nitro groups, halogen atoms, preferably by a hydroxyl group.

Eine gegebenenfalls substituierte Heterocyclusmethylgruppe für R1 bis R3 bedeutet vorzugsweise eine Thenyl-, Pyrrolmethyl-, Pyrrolidinylmethyl-, Piperidinmethyl-, Indolmethyl-, Imidazolmethyl-, Chinolinmethylgruppe, insbesondere die Indolylnethylgruppe und Imidazolmethylgruppe; sie kann substituiert sein vorzugsweise durch Halogenatome, niedere Alkyl- bzw. Alkoxygruppen mit 1 bis 4 Kohlenstoffatomen oder Nitrogruppen.An optionally substituted Heterocyclusmethylgruppe for R 1 to R 3 is preferably a thenyl, Pyrrolmethyl-, -pyrrolidinylmethyl-, P iperidinmethyl-, Indolmethyl-, imidazolemethyl-, Chinolinmethylgruppe, in particular the Indolylnethylgruppe and Imidazolmethylgruppe; it can be substituted, preferably by halogen atoms, lower alkyl or alkoxy groups having 1 to 4 carbon atoms or nitro groups.

Eine gegebenenfalls substituierte Aminogruppe für R1 bedeutet vorzugsweise eine Acylaminogruppe, insbesondere eine niedere Alkoxycarbonylgruppe mit bis zu 5 C-Atomen oder eine Benzyloxycarbonylgruppe.An optionally substituted amino group for R 1 is preferably an acylamino group, in particular a lower alkoxycarbonyl group with up to 5 carbon atoms or a benzyloxycarbonyl group.

Eine gegebenenfalls substituierte Arylgruppe für R1 bis R3 bedeutet vorzugsweise eine Phenyl- oder Naphthylgruppe, die gegebenenfalls durch Halogenatome, Hydroxylgruppen, Alkoxygruppen mit bis zu 4 Kohlenstoffatomen, Nitrogruppen, Trifluormethylgruppen und/oder niedere Alkylgruppen mit bis zu 4 Kohlenstoffatomen ein- bis dreifach substituiert ist.An optionally substituted aryl group for R 1 to R 3 preferably denotes a phenyl or naphthyl group which is optionally monosubstituted to trisubstituted by halogen atoms, hydroxyl groups, alkoxy groups having up to 4 carbon atoms, nitro groups, trifluoromethyl groups and / or lower alkyl groups having up to 4 carbon atoms is.

Eine gegebenenfalls substituierte Alkoxygruppe für R4 steht vorzugsweise für eine Alkoxygruppe mit 1 bis 4 C-Atomen, insbesondere für eine Methyl-, Äthyl-, Propyl-, Isopropyl-, Butyl-, Isobutyl-, sekundäre Butyl- oder tertiäre Butyloxygruppe, welche ihrerseits durch Halogenatome, Hydroxygruppen und/oder Alkoxygruppen mit bis zu 4 Kohlenstoffatomen ein-.bis dreifach substituiert sein können.An optionally substituted alkoxy group for R 4 preferably represents an alkoxy group having 1 to 4 carbon atoms, in particular a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl or tertiary butyloxy group, which in turn can be mono- to trisubstituted by halogen atoms, hydroxyl groups and / or alkoxy groups having up to 4 carbon atoms.

Eine gegebenenfalls substituierte Aralkoxygruppe für R4 bedeutet insbesondere die Benzyl-, Phenyläthyl-, Phenylpropyl-, Phenylisopropyloxygruppe, vorzugsweise die Benzyloxygruppe; sie kann substituiert sein durch 1 bis 2 Halogenatome oder Alkoxygruppen mit 1 bis 2 Kohlenstoffatomen.An optionally substituted aralkoxy group for R 4 means in particular the benzyl, phenylethyl, phenylpropyl, phenylisopropyloxy group, preferably the benzyloxy group; it can be substituted by 1 to 2 halogen atoms or alkoxy groups having 1 to 2 carbon atoms.

Eine gegebenenfalls substituierte Arylaminogruppe für R4 bedeutet vorzugsweise die Phenylaminogruppe, welche durch Halogenatome, Alkyl- bzw. Alkoxygruppen mit 1 bis 4 Kohlenstoffatomen oder durch eine Trifluormethylgruppe substituiert sein kann.An optionally substituted arylamino group for R 4 preferably denotes the phenylamino group, which can be substituted by halogen atoms, alkyl or alkoxy groups having 1 to 4 carbon atoms or by a trifluoromethyl group.

Eine gegebenenfalls substituierte Aralkylaminogruppe für R4 steht insbesondere für eine Benzyl-, Phenyläthyl-, Phenylpropyl- oder Phenylisopropylaminogruppe,welche ebenfalls wie vorstehend für die Arylaminogruppe beschrieben substituiert sein kann.An optionally substituted aralkylamino group for R 4 is in particular a benzyl, phenylethyl, phenylpropyl or phenylisopropylamino group, which can also be substituted as described above for the arylamino group.

Für den Fall, daß die Verbindungen der allgemeinen Formel (I) eine freie Säuregruppe enthalten (R4 = OH), können mit organischen und anorganischen Basen physiologisch verträgliche Additionssalze gebildet werden.In the event that the compounds of the general formula (I) contain a free acid group (R 4 = OH), physiologically compatible addition salts can be formed with organic and inorganic bases.

Als Beispiele solcher Salze seien vorzugsweise genannt Natriumsalze, Kalium-, Magnesium-, Ammonium-, Methylammonium-, Dimethylammoniumsalze oder auch das 2-Hydroxyäthylammoniumsalz.Examples of such salts are preferably sodium salts, potassium, magnesium, ammonium, methylammonium, dimethylammonium salts or the 2-hydroxyethylammonium salt.

Für den Fall, daß die erfindungsgemäßen Verbindungen der allgemeinen Formel (I) eine freie Aminogruppe aufweisen, können ebenfalls mit Säuren physiologisch verträgliche Additionssalze gebildet werden.In the event that the compounds of the general formula (I) according to the invention have a free amino group, addition salts which are physiologically compatible can also be formed with acids.

Als Beispiele solcher Salze seien genannt Halogenide, vorzugsweise Chloride, Sulfate, Citrate, Tartrate, Maleinate und Sulfonate.Examples of such salts are halides, preferably chlorides, sulfates, citrates, tartrates, maleinates and sulfonates.

Überraschenderweise zeigen die erfindungsgemäßen Verbindurgen der allgemeinen Formel (I) eine vorteilhaftere Wirk- sankiet als die aus dem Stand der Technik bekannten Indometacinserinderivate der DOS 2 413 125.
Die erfindungsgemäßen Verbindungen stellen somit eine Bereicherung der Pharmazie dar.Surprisingly, the compounds of general formula (I) according to the invention show a more advantageous active ingredient than the indomethacinserine derivatives of DOS 2 413 125 known from the prior art.
The compounds according to the invention thus represent an enrichment of pharmacy.

Verwendet man ACE-OH und Chlorameisensäureester als Ausgangsverbindungen, so kann der Reaktionsablauf der Variante a) durch das folgende Formelschema wiedergegeben werden:

Figure imgb0007
If ACE-OH and chloroformate are used as starting compounds, the reaction sequence of variant a) can be represented by the following formula:
Figure imgb0007

Die als Ausgangsverbindungen verwendbaren Chlorameisensäureester der allgemeinen Formel (II) sind bekannt und die als Ausgangsverbindung verwendeteACE-OH ist ebenfalls bekannt (DOS 2 234 651).The chloroformic acid esters of the general formula (II) which can be used as starting compounds are known and the ACE-OH used as starting compound is also known (DOS 2 234 651).

Die als Zwischenprodukt gebildeten gemischten Anhydride der allgemeinen Formel (III) sind neu, können aber nicht indentifiziert werden, da sie sich - wie auch der überwiegende Teil der literaturbekannten gemischten Anhydride - bei der Aufarbeitung zersetzen (vgl. Houben-Weyl, Methoden der Organischen Chemie, 4. Auflage, Band 15/2, Seite 17, 3. Absatz).The mixed anhydrides of the general formula (III) formed as an intermediate are new, but cannot be identified because, like the majority of the mixed anhydrides known in the literature, they decompose during processing (cf.Houben-Weyl, Methods of Organic Chemistry , 4th edition, volume 15/2, page 17, 3rd paragraph).

Die als Ausgangsverbindungen verwendbaren Verbindungen der allgemeinen Formel (IV) sind weitgehend literaturbekannt oder können nach bekannten Methoden hergestellt werden (vgl. u. a. Houben-Weyl, Methoden der organischen Chemie, 4. Auflage, Bd 15/1 u 2).The compounds of the general formula (IV) which can be used as starting compounds are largely known from the literature or can be prepared by known methods (cf., inter alia, Houben-Weyl, Methods of Organic Chemistry, 4th Edition, Vol 15/1 and 2).

Die Reaktion erfolgt zweckmäßig in Gegenwart von Verdünnungsmitteln. Als Verdünnungsmittel kommen inerte organische Lösungsmittel in Frage, insbesondere solche, die polar aprotisch sind. Beispielhaft seien genannt Tetrahydrofuan, Dioxan, Dimethylformamid, Hexamethylphosphorsäuretriamid.The reaction is conveniently carried out in the presence of diluents. Inert organic solvents are suitable as diluents, in particular those which are polar aprotic. Examples include tetrahydrofuan, dioxane, dimethylformamide, hexamethylphosphoric triamide.

Die Reaktion erfolgt zweckmäßig in Gegenwart von Säurebindern. Als Säurebinder können alle üblichen Mittel verwendet werden, welche den freiwerdenden Chlorwasserstoff zu binden vermögen. Hierzu gehören vorzugsweise Alkalihydroxyde und -carbonate oder organische Basen wie Pyridin und Triäthylarin.The reaction is conveniently carried out in the presence of acid binders. All customary agents which are able to bind the hydrogen chloride released can be used as the acid binder. These preferably include alkali hydroxides and carbonates or organic bases such as pyridine and triethylarin.

Die Reaktionstemperaturen liegen zweckmäßigerweise unterhalb von 0° C, da andernfalls Racemisierungen auftreten; sie können in einen gewissen Bereich variiert werden. Im allgemeinen arbeitet mar bei Temperaturen zwischen Oo bis -25o C, vorzugsweise zwischen -10° und -20° C.The reaction temperatures are expediently below 0 ° C., since otherwise racemizations occur; they can be varied within a certain range. In general, mar works at temperatures between O o to -25 o C, preferably between -10 ° and -20 ° C.

Die Umsetzung erfolgt üblicherweise bei Normaldruck.The reaction is usually carried out at normal pressure.

Bei der Durchführung des erfindungsgemäßen Verfahrens setzt man vorzugsweise auf 1 Mol ACE-OH, .1 Mol Chlorameisensäureester, 1 Xol des Aminosäurederivates sowie 1 Mol des Säurebinders ein.When carrying out the process according to the invention, preference is given to using 1 mol of ACE-OH, .1 mol of chloroformate, 1 xol of the amino acid derivative and 1 mol of the acid binder.

Die Feaktionszeit liegt zwischen 6 und 24 Stunden, vorzugsweise bei 14 bis 20 Stunden.The reaction time is between 6 and 24 hours, preferably 14 to 20 hours.

Die Aufarbeitung erfolgt vorzugsweise durch Eindampfen im Vakuum, Aufnehmen in eins der üblichen organischen Lösungsmittel, Neutralwaschen, gegebenenfalls Reinigen an Kieselgel und Rekristallisation.Working up is preferably carried out by evaporation in vacuo, taking up in one of the customary organic solvents, neutral washing, optionally cleaning on silica gel and recrystallization.

Verwendet man für die Reaktion anstelle eines gemischten Anhydrids von ACE-OH einen aktivierten Ester der allgemeinen Formel (V), so kann die Reaktion der Variante b) durch das folgende Reaktionsschema wiedergegeben werden:

Figure imgb0008
If an activated ester of the general formula (V) is used for the reaction instead of a mixed anhydride of ACE-OH, the reaction of variant b) can be represented by the following reaction scheme:
Figure imgb0008

Die als Reaktionspartner verwendeten Verbindungen der allgemeinen Formel (V) sind bisher nicht bekannt, können aber in an sich bekannter Weise durch Umsetzung von 1 Mol ACE-OH und 1 Mcl des entsprechend substituierten Phenols in einem polar aprotischen organischen Lösungsmittel, wie z.B. Tetrahydrofuran, in Gegenwart von 1 Mol eines Carbodiimids, wie z.B. Dicyclohexycarbodiimid oder Carbonyldiimidazol in etwa 1 1/2-stündiger Reaktionszeit bei Raumtemperatur erhalten werden.The compounds of the general formula (V) used as reactants are not yet known, but can be known in a manner known per se by reacting 1 mol of ACE-OH and 1 M cl of the correspondingly substituted phenol in a polar aprotic organic solvent, such as, for example, tetrahydrofuran. in the presence of 1 mole of a carbodiimide, such as D icyclohexycarbodiimid or carbonyldiimidazole are obtained in approximately 1 1/2 hours of reaction at room temperature.

Das erfindungsgem'äße Verfahren (V) → (I) erfolgt zweckmäßig in Gegenwart von Verdünnungsmitteln. Als Verdünnungsmittel kommen die für diese Reaktion literaturbekannten organischen Lösungsmittel, vorzugsweise Dimethylformamid, Dioxan, Pyridin oder deren Gemische mit Wasser in Frage.Process (V) → (I) according to the invention is advantageously carried out in the presence of diluents. Suitable diluents are the organic solvents known for this reaction, preferably dimethylformamide, dioxane, pyridine or mixtures thereof with water.

Soweit Additionssalze von (IV) zu Peaktionen verwendet werden, erfolgt das Verfahren zweckmäßig in Gegenwart von Säurebindern. Beispielhaft seien genannt Alkalihydroxyde, -carbonate oder starke organische Anine, vorzugsweise Triäthylamin.If addition salts of (IV) are used for reactions, the process is advantageously carried out in the presence of acid binders. Examples include alkali metal hydroxides, carbonates or strong organic anines, preferably triethylamine.

Die Reaktionstemperaturen können in einem gewissen Bereich variiert werden. Normalerweise arbeitet man bei 15-25° C, da bei niedrigeren Terperaturen die Reaktionszeiten unverhältnisräßig verlängert werden, bei höheren Temperaturen jedoch die Racematbildung gefördert wird. Eine gewisse Racematbildung ist auch bei der Reaktion bei Raumtemperatur nicht auszuschließen.*
Das Verfahren wird üblicherweise bei Normaldruck durchgeführt.The reaction temperatures can be varied within a certain range. Normally one works at 15-25 ° C, since the reaction times are extended disproportionately at lower temperatures, but the formation of racemates is promoted at higher temperatures. A certain racemate formation cannot be ruled out even in the reaction at room temperature.
The process is usually carried out at normal pressure.

Bei der Durchführung des erfindungsgemäßen Verfahrens wird vorzugsweise pro Mol des aktivierten Esters(V).1 Xol des Aminosäurederivates (IV) eingesetzt. Die Aufarbeitung erfolgt zweckräßigerweise durch Verdünnen des Ansatzes mit Wasser, Aufnegmen in einem geeigneten organischen Lösungsmittel, Neutralisieren, Eindampfen und Rekristallisieren aus geeigneten Lösungsmitteln.When carrying out the process according to the invention, 1 xol of the amino acid derivative (IV) is preferably used per mole of the activated ester (V). The working up is expediently carried out by diluting the mixture with water, taking it up in a suitable organic solvent, neutralizing, evaporating and recrystallizing from suitable solvents.

Für den Fall, daß die Aminosäurederivate der allgemeinen Formel (VI) esterartig mit ACE-OH verknüpft werden sollen, kann die Reaktion der Variante c) durch das nachfolgende Reaktionsschema wiedergegeben werden:

Figure imgb0009
In the event that the amino acid derivatives of the general formula (VI) are to be linked ester-like with ACE-OH, the reaction of variant c) can be represented by the following reaction scheme:
Figure imgb0009

Die als Ausgangsverbindungen verwendeten Serinderivate der allgemeinen Formel (VI) sind bekannt. Die Peaktion erfolgt vorzugsweise in Gegenwart von Verdünnungsmitteln. Als Verdännungsmittel können polar aprotische organische Lösungsmittel verwendet werden. Beispielhaft seien genannt Tetrahydrofuran, Dioxan, Dimethylformamid, Hexamethylphosphorsäuretriamid. Die erfindungsgeräße Reaktion erfolgt vorzugsweise in Gegenwart eines wasserentziehenden Mittels. Beispielhaft seien genannt Dicyclohexylcarbodiinid oder Carbonyldiimidazol in Gegenwart katalytischer Mengen eines basischen Katalysators, vorzugsweise Natriunhydrid.The serine derivatives of the general formula (VI) used as starting compounds are known. The reaction is preferably carried out in the presence of diluents. Polar aprotic organic solvents can be used as diluents. Examples include tetrahydrofuran, dioxane, dimethylformamide, hexamethylphosphoric triamide. The reaction according to the invention is preferably carried out in the presence of a dehydrating agent. Examples include dicyclohexylcarbodiinide or carbonyldiimidazole in the presence of catalytic amounts of a basic catalyst, preferably sodium hydride.

Die Reaktionstemperaturen können in größerer Breite variiert werden; üblicherweise arbeitet man zwischen 10 und 40°C, vorzugsweise zwischen 15 und 25°C.The reaction temperatures can be varied over a wide range; Usually one works between 10 and 40 ° C, preferably between 15 and 25 ° C.

Zweckmäßigerweise bringt man zunächst 1 Mol der ACE-OH mit 1 Mol Carbonyldiimidazol zur Reaktion und fügt 1 Mol des Aminosäurederivates erst nach beendeter C02-Entwicklung hinzu. Die Aufarbeitung erfolgt in üblicher Weise, vorzugsweise durch Eindampfen im Vakuum, Aufnehmen in einen geeigneten Lösungsmittel und Reinigen an Kieselgel. Die Abspaltung der Aminoschutzgruppe R6 erfolgt nach den in der Peptidchemie üblichen literaturbekannten Methoden.Appropriately, 1 mol of the ACE-OH is first reacted with 1 mol of carbonyldiimidazole and 1 mol of the amino acid derivative is only added after the CO 2 evolution has ended. Working up is carried out in the usual way, preferably by evaporation in vacuo, taking up in a suitable solvent and cleaning on silica gel. The amino protective group R 6 is cleaved off according to the methods known from the literature in peptide chemistry.

Als neue Wirkstoffe seien beispielhaft genannt:

  • N-ACE-Serinmethylester, N-ACE-Serin, N-ACE-Methionin,
  • N-ACE-Tyrosin, N-ACE-Tryptophan, N-ACE-DL-Threonin,
  • N-ACE-Phenylalanin, N-ACE-Serin-N'-methylanid,
  • N-ACE-Histidinriethylester, N-ACE-Serinbenzylester,
  • 0-ACE-Serinnethylester, O-ACE-Serinäthylester,
  • N-ACE-Phenylalanyltyrosinmethylester,
  • N-ACE-Glycylalanylphenylalaninmethylester,
  • Nα-ACE-Nγ-benzyloxycarbonyldiaminobutyrylphenylalanylphenyl= alaninmethylester.
Examples of new active ingredients are:
  • N-ACE serine methyl ester, N-ACE serine, N-ACE methionine,
  • N-ACE tyrosine, N-ACE tryptophan, N-ACE-DL-threonine,
  • N-ACE-phenylalanine, N-ACE-serine-N'-methylanide,
  • N-ACE histidine diethyl ester, N-ACE serine benzyl ester,
  • 0-ACE serine methyl ester, O-ACE serine ethyl ester,
  • N-ACE-phenylalanyl tyrosine methyl ester,
  • N-ACE-glycylalanylphenylalanine methyl ester,
  • N α -ACE-N γ -benzyloxycarbonyldiaminobutyrylphenylalanylphenyl = alanine methyl ester.

Als ACE sei hier und im weiteren Verlauf der Rest

Figure imgb0010
verstanden.As ACE, the rest is here and later
Figure imgb0010
 Roger that.

Die neuen Wirkstoffe können in bekannter Weise in die üblichen Formulierungen überführt werden wie Tabletten, Kapseln, Dragees, Pillen, Granulate, Aerosole, Sirupe, Emulsionen, Suspensionen, Lösungen, Salben, Gele, Cremes, Gallerten, unter Verwendung inerter, nichttoxischer; pharmazeutisch geeigneter Trägerstoffe oder Lösungsmittel. Hierbei soll die therapeutisch wirksame Verbindung jeweils in einer Konzentration von etwa 0,5 bis 90 Gew.-% der Gesamtmischung vorhanden sein, d.h. in Mengen, die ausreichend sind, um den angegebenen Dosierungsspielraum zu erreichen.The new active compounds can be converted in a known manner into the customary formulations, such as tablets, capsules, dragees, pills, granules, aerosols, syrups, emulsions, suspensions, solutions, ointments, gels, creams, jellies, using inert, non-toxic; pharmaceutically acceptable carriers or solvents. Here, the therapeutically active compound should be present in a concentration of about 0.5 to 90% by weight of the total mixture, i.e. in amounts sufficient to achieve the dosage range indicated.

Die Formulierungen werden beispielsweise hergestellt durch Vorstrecken der Wirkstoffe mit Lösungsmitteln und/oder Trägerstoffen, gegebenenfalls unter Verwendung von Emulgiermitteln und/oder Dispergiermitteln, wobei z.B. im Falle der Benutzung von Wasser als Verdünnungsmittel gegebenenfalls organische .Lösungsmittel als Hilfslösungsnittel verwendet werden können.The formulations are prepared, for example, by pre-stretching the active ingredients with solvents and / or carriers, optionally using emulsifiers and / or dispersants, e.g. if water is used as a diluent, organic solvents can optionally be used as auxiliary solvents.

Als Hilfsstoffe seien beispielhaft aufgeführt:

  • Wasser, nichttoxische organische Lösungsmittel wie Paraffine (z.B. Erdölfraktionen), pflanzliche Öle (z.B. Erdnuß-/Sesamöl), Alkohole (z.B. Äthylalkohol, Glycerin), Glykole (z.B. Propylenglykol, Polyäthylenglykol); feste Trägerstoffe wie z.B. natürliche Gesteinsmehle. (z.B. Kaoline, Tonerden, Talkun, Kreide), synthetische Gesteinsrehle (z.B. hochdisperse Kieselsäure, Silikate), Zucker (z.B. Reh-, Milch- und Traaubenzuoker); Emulgiermittel wie nichtionogene und. anionische Enulgatoren (z.B. Polyoxyäthylen-Fettsäureester, Polyoxyäthylen-Fettalkohol-Xther, Alkylsulfonate und Arylsulfonate), Dispergiermittel (z.B. Lignin, Sulfitablaugen, Methylcellulose, Stärke und Polyvinylpyrrolidon) und Gleitmittel (z.B. Magnesiumstearat, Talkum, Stearinsäure und Natriumlaurylsulfat).
Examples of auxiliary substances are:
  • Water, non-toxic organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. peanut / sesame oil), alcohols (e.g. ethyl alcohol, glycerin), glycols (e.g. propylene glycol, polyethylene glycol); solid carriers such as natural rock powder. (eg kaolins, clays, talc, chalk), synthetic rock (eg highly disperse silica, silicates), sugar (eg roe deer, milk and grape juices); Emulsifiers such as nonionic and. anionic enulsifiers (e.g. polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, alkyl sulfonates and arylsulfonates), dispersants (e.g. lignin, sulfite lye, methyl cellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl).

Die Applikation erfolgt in üb1icher Weise, vorzugsweise oral oder parenteral, lckal,intramuskulär oder intravenös.The application takes place in the usual way, preferably orally or parenterally, lckally, intramuscularly or intravenously.

Im Falle der oralen Anwendung können Tabletten, selbstverständlich außer den genannten Trägerstoffen auch Zusätze wie Natriuncitrat, Calciumcarbomat und Dicalciumphosphat, zusammen mit verschiedenen Zuschlagstoffen wie Stärke, vorzugsweise Kartoffelstärke, Gelatine und dergleichen enthalten. Weiterhin können Gleitnittel wie Magnesiumstearat, Natriumlaurylsulfat und Talkum zum Tablettieren mitverwendet werden. Im Falle wäßriger Suspensionen und/oder.' Elixiere, die für orale Anwendungen gedacht sind, können die Wirkstoffe außer mit den genannten Hilfsstoffen mit verschiedenen Geschmacksaufbesserern oder Farbstoffen versetzt werden.In the case of oral use, tablets, of course in addition to the carrier substances mentioned, can also contain additives such as sodium citrate, calcium carbomate and dicalcium phosphate, together with various additives such as starch, preferably potato starch, gelatin and the like. Glidants such as magnesium stearate, sodium lauryl sulfate and talc can also be used for tableting. In the case of aqueous suspensions and / or. ' Elixirs, which are intended for oral applications, can be mixed with various flavor enhancers or colorants in addition to the additives mentioned.

Für den Fall der parenteralen Anwendung können Lösungen der Wirkstoffe unter Verwendung geeigneter flüssiger Trägermaterialien eingesetzt werden.In the case of parenteral use, solutions of the active ingredients can be used using suitable liquid carrier materials.

Für den Fall der lokalen Anwendung kommen vorzugsweise Lösungen, Emulsionen, Salben, Gele, Cremes,Aerosole oder Gallerten mit geeigneten vorgenannten Hilfsstoffen in Betracht.In the case of local application, preference is given to solutions, emulsions, ointments, gels, creams, aerosols or jellies with suitable auxiliaries mentioned above.

Im allgemeinen hat es sich als vorteilhaft erwiesen, bei oraler Applikation Mengen von etwa 1 bis 100 mg, insbesondere 10 bis 40 mg pro Dosis bei 2- bis 3-maliger täglicher Verabreichung zur Erzielung wirksamer Ergebnisse einzusetzen, bei rektaler Applikation beträgt die Dosierung etwa 10 bis 200, insbesondere 30 bis 80 mg pro Dosis.In general, it has proven to be advantageous to use amounts of about 1 to 100 mg, in particular 10 to 40 mg per dose in the case of oral administration in order to achieve effective results when administered 2 to 3 times a day; in the case of rectal administration, the dosage is about 10 up to 200, especially 30 to 80 mg per dose.

Beispiel 1example 1 N-ACE-SerinmethylesterN-ACE serine methyl ester

Figure imgb0011
5 g (0,012 Mol) ACE-OH werden in 50 ml absolutem Tetrahydrofuran gelöst, mit 1,8 ml (0,0131 Mol) Triäthylarin versetzt, auf -10°C gekühlt und während einer halben Stunde tropfenweise mit 1,7 ml (0,0131 Mol) Chlorameisensäure-n-butylester versetzt. Das so gebildete gemischte Anhydrid ACE-O-COO-n-C4H9 kann nicht isoliert werden, da es sich bereits bei Raumtemperatur zersetzt. Es wird - wie auch in den weiteren Beispielen - in Lösung weiterverarbeitet, indem man 2,05 g (0,0131 Mol) L-Serinnethylester, gelöst in 20 ml Dimethylformamid und weitere 1,8 ml Triäthylamin bei -10°C in obige Lösung eintropft. Nach einstündigem Rühren bei -10°C und weiteren 12- stündigem Stehen bei -18°C wird der Ansatz bei.3 Torr und 30°C eingedampft, der Rückstand in Chloroform gelöst, mit 2 nHCl und dann mit Wasser neutralgewaschen, über Na2So4 getrocknet, filtriert und eingedampft. Nach Reinigen an Kieselgel mit einem Gemisch aus Chloroform/Methanol, Eindampfen, Aufnehmen des Rückstandes in 50 nl Äthanol und Zufügen von Wasser bis zur beginnenden Kristallisation werden 5,05 g ACE-Serinmethylester (= 82,1 % d.Th.) vom Pp. 88°C erhalten.
Figure imgb0012
 = -2,6 (c = 0,5; Dimethylformanid).
Figure imgb0011
 5 g (0.012 mol) of ACE-OH are dissolved in 50 ml of absolute tetrahydrofuran, 1.8 ml (0.0131 mol) of triethylarin are added, the mixture is cooled to -10.degree. C., and 1.7 ml (0 , 0131 mol) of chloroformate n-butyl ester. The mixed anhydride ACE-O-COO-nC 4 H 9 thus formed cannot be isolated since it decomposes at room temperature. As in the other examples, it is processed further in solution by adding 2.05 g (0.0131 mol) of L-serine methyl ester, dissolved in 20 ml of dimethylformamide and a further 1.8 ml of triethylamine at -10 ° C. in the above solution drips in. After stirring for one hour at -10 ° C and standing for another 12 hours at -18 ° C, the mixture is evaporated at 3 torr and 30 ° C, the residue is dissolved in chloroform, washed neutral with 2 nHCl and then with water, over Na 2 So 4 dried, filtered and evaporated. After cleaning on silica gel with a mixture of chloroform / methanol, evaporation, taking up the residue in 50 nl of ethanol and adding water until crystallization begins, 5.05 g of ACE serine methyl ester (= 82.1% of theory) of pp Obtained 88 ° C.
Figure imgb0012
 = -2.6 (c = 0.5; dimethylformanide).

Für C 25 H 25 CIN 2 O8

Figure imgb0013
In gleicher Weise können hergestellt werden:For C 25 H 25 CIN 2 O 8
Figure imgb0013
 The following can be produced in the same way:

Beispiel 2Example 2 N-ACE-SerinN-ACE serine

Figure imgb0014
mit L-Serin; Fp. 133°C, Ausbeute 70,8 % der Theorie. Für C24H23CIN2O8
Figure imgb0015
 = +6.8 (c = 0,5; Dimethylformamid)
Figure imgb0016
Figure imgb0014
 with L-serine; Mp 133 ° C, yield 70.8% of theory. For C 24 H 23 CIN 2 O 8
Figure imgb0015
 = +6.8 (c = 0.5; dimethylformamide)
Figure imgb0016

Beispiel 3Example 3 N-ACE-MethioninN-ACE methionine

Figure imgb0017
Fp. 165°C, Ausbeute 70,1 % der Theorie.
Figure imgb0018
 = -0,8 (c = 0,5; Für C26H27 CIN2O7s Dimethylformamid
Figure imgb0019
Figure imgb0017
 Mp 165 ° C, yield 70.1% of theory.
Figure imgb0018
 = -0.8 (c = 0.5; For C 26 H 27 CIN 2 O 7 s dimethylformamide
Figure imgb0019

Beispiel 4Example 4 N-ACE-TyrosinN-ACE tyrosine

Figure imgb0020
Fp. 111°C, Ausbeute 34.7 % der Theorie.
Figure imgb0021
 +7,3 (C = 0, 5; Dimethylformamid) Für C30H27CIN2O8 Für C30H27CIN2O8
Figure imgb0022
Figure imgb0020
 Mp 111 ° C, yield 34.7% of theory.
Figure imgb0021
 +7.3 (C = 0.5; dimethylformamide) For C 30 H 27 CIN 2 O 8 For C 30 H 27 CIN 2 O 8
Figure imgb0022

Beispiel 5Example 5 N-ACE-TryptophanN-ACE tryptophan

Figure imgb0023
sintert bei 120-150°C, Ausbeute 65,3 % der Theorie. Für C32H28CIN3O7
Figure imgb0024
=+ 9,4 (c = 0,5; Dimethylformamid)
Figure imgb0025
Figure imgb0023
 sinters at 120-150 ° C, yield 65.3% of theory. For C 32 H 28 CIN 3 O 7
Figure imgb0024
 = + 9.4 (c = 0.5; dimethylformamide)
Figure imgb0025

Beispiel 6Example 6 N-ACE-DL-ThreoninN-ACE-DL-threonine

Figure imgb0026
Fp. 119°C, Ausbeute 47 % der Theorie
Figure imgb0027
=-0,8 (c=0,5; Für C25H25CIN2O8 Dimethylformamid) Für C25H25CIN2O8
Figure imgb0028
Figure imgb0026
 Mp 119 ° C , yield 47 % of theory
Figure imgb0027
 = -0.8 (c = 0.5; for C 25 H 25 CIN 2 O 8 dimethylformamide) for C 25 H 25 CIN 2 O 8
Figure imgb0028

B e i s p i e l 7Example 7 N-ACE-PhcnylalaninN-ACE phynylalanine

Figure imgb0029
Fp. 174°C, Ausbeute 57,8 % der Theorie.
Figure imgb0030
 +4,9 (c = 0,5; Dimethylformamid) Für C30H27Cl N2O7
Figure imgb0031
Figure imgb0029
 Mp 174 ° C, yield 57.8% of theory.
Figure imgb0030
 +4.9 (c = 0.5; dimethylformamide) For C 30 H 27 Cl N 2 O 7
Figure imgb0031

Beispiel 8Example 8 N-ACE-AlaninN-ACE alanine

Figure imgb0032
Fp. 140°C, Ausbeute 48 % der Theorie.
Figure imgb0033
=-4,6(c = 0,5; Für C24H23 Cl N2O7 Dimethylformamid) Für C24H23ClN2O7
Figure imgb0034
Figure imgb0032
 Mp 140 ° C, yield 48% of theory.
Figure imgb0033
 = -4.6 (c = 0.5; for C 24 H 23 Cl N 2 O 7 dimethylformamide) for C 24 H 23 ClN 2 O 7
Figure imgb0034

Beispiel 9Example 9 N-ACE-PhenylslycinN-ACE phenylslycine

Figure imgb0035
Fp. 179-182°C, Ausbeute 57,6 % der Theorie.
Figure imgb0036
 = +61,8 Für C29H25ClN2O7 (c = 0,5; Dimethylformamid
Figure imgb0037
Figure imgb0035
 Mp 179-182 ° C, yield 57.6% of theory.
Figure imgb0036
 = +61.8 For C 29 H 25 ClN 2 O 7 (c = 0.5; dimethylformamide
Figure imgb0037

Beispiel 10Example 10 N-ACE-DL-O-MethylserinN-ACE-DL-O-methylserine

Figure imgb0038
Fp. 96°C, Ausbeute 39 % der Theorie.
Figure imgb0039
 = 0 (c = 0,5; Di-Für C25H25ClN2O8 methylformamid)
Figure imgb0040
Figure imgb0038
 Mp 96 ° C, yield 39% of theory.
Figure imgb0039
 = 0 (c = 0.5; Di-For C 25 H 25 ClN 2 O 8 methylformamide)
Figure imgb0040

B e i a p i e 1 11B e i a p i e 1 11 N-ACE-DL-SerinmethylamidN-ACE-DL-serine methyl amide

Figure imgb0041
Fp. 141°C, Ausbeute 42,3 % der Theorie.
Figure imgb0042
 = +3,2 (c = 0,5; Für C25H26ClN3O7 Dinethylformamid)
Figure imgb0043
Figure imgb0041
 Mp 141 ° C, yield 42.3% of theory.
Figure imgb0042
 = +3.2 (c = 0.5; for C 25 H 26 ClN 3 O 7 dinethylformamide)
Figure imgb0043

Beispiel 12Example 12 ACE-2,4,5-TrichlorphenylesterACE-2,4,5-trichlorophenyl ester

Figure imgb0044
2 g (0,0048 Mol) ACE-OH und 1 g (0,0051 Mol) 2,4,5-Trichlor= phenol werden in 25 ml Tetrahydrofuran gelöst, mit 1 g (0,0048 Mol) Dicyclohexylcarbodiirid versetzt und 1 1/2 Std. bei Paumtemperatur gerührt. Anschließend wird der ausgefallene Dicyclohexylharnstoff abgesaugt, die Lösung eingedampft und mit 20 ml Äthanol verrieben. Nach beendeter Kristallisation wird abgesaugt und der Kristallbrei mit Äthanol und Petroläther gewaschen. Fp. 132-134°C, Ausbeute 2,3 g = 80,4 % der Theorie.
Figure imgb0044
 2 g (0.0048 mol) ACE-OH and 1 g (0.0051 mol) 2,4,5-trichlor = phenol are dissolved in 25 ml tetrahydrofuran, 1 g (0.0048 mol) dicyclohexylcarbodiiride is added and 1 1 / Stirred at break temperature for 2 hours. The precipitated dicyclohexylurea is then suctioned off, the solution is evaporated and triturated with 20 ml of ethanol. After crystallization is suctioned off and the crystal slurry washed with ethanol and petroleum ether. Mp 132-134 ° C, yield 2.3 g = 80.4% of theory.

Es handelt sich um ein Zwischenprodukt für die Herstellung der folgenden Verbindungen.It is an intermediate for the preparation of the following compounds.

Beispiel 13Example 13 N-ACE-HistidinmethylesterN-ACE histidine methyl ester

Figure imgb0045
4,86 g (0,02 Mol) L-Histidinnethylesterdihydroehlorid und 8,3 nl (0,06 Mol)Triäthylanin werden in 100 ml Dimethylformamid gelöst und bei -10°C mit 5,67 g (0,02 Mol) der im Beispiel 12 beschriebenen Verbindung versetzt. Nach mehrstündigem Rühren und Stehen bei Raumtemperatur wird der Ansatz nit Wasser verdünnt und rehrfach mit Äthylenchlorid extrahiert. Die Äthylenchloridlösung wird mit nHCl ausgeschüttelt und mit Wasser neutralgewaschen. Die organische Phase wird anschlieaend über Na2SO4 getrocknet, filtriert und eingedampft. Der Rückstand wird in Chloroform/Xethamol (9:1) an Kieselgel gereinigt. Fp. 119°C, Ausbeute 3,7 g = 34 % der Theorie Für C28H27ClN4O7
Figure imgb0046
 =+3,5 (c = 3,5; Dirmethylformamid) C28H27ClN4O7
Figure imgb0047
Figure imgb0045
 4.86 g (0.02 mol) of L-histidine methyl ester dihydroehloride and 8.3 nl (0.06 mol) of triethylanine are dissolved in 100 ml of dimethylformamide and at -10 ° C with 5.67 g (0.02 mol) of the Example 12 compound added. After stirring for several hours and standing at room temperature, the mixture is diluted with water and extracted repeatedly with ethylene chloride. The ethylene chloride solution is shaken out with nHCl and washed neutral with water. The organic phase is then dried over Na 2 SO 4 , filtered and evaporated. The residue is purified in chloroform / xethamol (9: 1) on silica gel. Mp 119 ° C, yield 3.7 g = 34% of theory for C 28 H 27 ClN 4 O 7
Figure imgb0046
 = + 3.5 (c = 3.5; dirmethylformamide) C 28 H 27 ClN 4 O 7
Figure imgb0047

Beispiel 14Example 14 N-ACE-SerinbenzylesterN-ACE serine benzyl ester

Figure imgb0048
analog Beispiel 13 unter Verwendung von L-Serinbenzylester. Fp. 158-159°C,
Figure imgb0049
 = 10,9° (c = 0,5; Dimethylformamid) Ausbeute 67 % der Theorie. Für C31HZ9C1N208
Figure imgb0050
Figure imgb0048
 analogously to Example 13 using L-serine benzyl ester. Mp 158-159 ° C,
Figure imgb0049
 = 10.9 ° (c = 0.5; dimethylformamide) Yield 67% of theory. For C 31 H Z9 C1N 2 0 8
Figure imgb0050

B e i s D i e 1 15B e i D 1 15 O-ACE-N-Boc-SerinrinmethylesterO-ACE-N-Boc-Serinrin methyl ester

Figure imgb0051
4,15 g (0,01 Mol) ACE-OH werden in 15 ml Tetrahydrofuran gelöst, mit 1,78 g (0,011 Mol) 1,1'-Carbodiinidazol versetzt und bis zur Beendigung der C02-Entwicklung gerührt.
Figure imgb0051
 4.15 g (0.01 mol) of ACE-OH are dissolved in 15 ml of tetrahydrofuran, treated with 1.78 g (0.011 mol) of 1,1'-carbodiinidazole and stirred until the CO 2 evolution has ended.

In dieser Lösung wird eine Lösung von 2,25 g (0,01 Mol) N-Boc-Serinmethylester in 10 ml Tetrahydrofuran in Gegenwart katalytischer Mengen von Natriumhydrid hinzugegügt und 7 Stunden bei 35°C gerührt. Anschließend wird die Lösung bei 3 Torr eingedampft, der Rückstand wird in Äthylacetat aufgenommen und an Kieselgel gereinigt. Die Verbindung ist ein Öl. Ausbeute 5,1 g (= 82 % der Theorie).In this solution, a solution of 2.25 g (0.01 mol) of N-Boc-serine methyl ester in 10 ml of tetrahydrofuran is added in the presence of catalytic amounts of sodium hydride and the mixture is stirred at 35 ° C. for 7 hours. The solution is then evaporated at 3 torr, the residue is taken up in ethyl acetate and purified on silica gel. The compound is an oil. Yield 5.1 g (= 82% of theory).

Beispiel 16Example 16 O-ACE-SernmethylestertrifluoracetatO-ACE-methyl ester trifluoroacetate

Figure imgb0052
Die Verbindung entsteht in bekannter Weise durch Versetzen der Verbindung aus Beispiel 15 mit Trifluoressigsäure. Fp. 69-70°C, Ausbeute 65 % der Theorie.
Figure imgb0053
 = +0,8 (c = 0,5; Dimethylformamid) FÜr C25H25C1N2O8 C2HF3O2
Figure imgb0054
Figure imgb0052
 The compound is formed in a known manner by adding trifluoroacetic acid to the compound from Example 15. Mp 69-70 ° C, yield 65% of theory.
Figure imgb0053
 = +0.8 (c = 0.5; dimethylformamide) FOR C 25 H 25 C1N 2 O 8 C 2 HF 3 O 2
Figure imgb0054

Beispiel 17Example 17 0-ACE-N-Boe-Serinäthylester0-ACE-N-Boe serine ethyl ester

Figure imgb0055
analog Beispiel 15 aus 10,15 g ACE-OH und 5,7 g Boc-Serin= äthylester. Fp. 99-100°C, Ausbeute 6,2 g. (Rohprodukt)
Figure imgb0055
 analogous to Example 15 from 10.15 g ACE-OH and 5.7 g Boc-Serin = ethyl ester. Mp 99-100 ° C, yield 6.2 g. (Raw product)

Beispiel 18Example 18 0-ACE-Serinäthylester trifluoracetat0-ACE serine ethyl trifluoroacetate

Figure imgb0056
Analog Beispiel 16 aus der in Beispiel 17 beschriebenen Verbindung Fp. 56-58°C,
Figure imgb0057
 = -2,4 (c = 0,5; Dimethylformamid); Ausbeute 77 % der Theorie. Für C26H27ClN208 C2HF302
Figure imgb0058
Figure imgb0056
 Analogously to example 16 from the compound described in example 17, mp. 56-58 ° C.,
Figure imgb0057
 = -2.4 (c = 0.5; dimethylformamide); Yield 77% of theory. For C 26 H 27 ClN 2 0 8 C 2 HF 3 0 2
Figure imgb0058

Beispiel 19Example 19 N-ACE-PhenvlalanyltyrosinmethylesterN-ACE phenvlalanyl tyrosine methyl ester

Figure imgb0059
Eine Suspension von 0,005 Mol Phenylalanyltyrosinmethylestertrifluoracetat in 15 nl.absolutem Dimethylformamid wird unter Rühren bei 0°C zunächst nit 0,005 Mol Triäthylamin und nach 10 Minuten nit 0,005 Mol ACE-2,4,5-trichlorphenylester versetzt. Nach zweistündigem Rühren, zuletzt bei Rauntenperatur, wird das Reaktionsgemisch rit 150 ml Wasser versetzt, dreimal mit Xthylacetat extrahiert und die organische Phase dreimal mit nHCl-Lösung ausgeschüttelt. Anschließend wird die Lösung mit Wasser neutralgewaschen, über Na2SO4 getrocknet und eingedampft. Nach Rekristallisation aus Aceton/Petroläther werden 84 % der Theorie an N-ACE-Phenylalanyltyrosinmethyl= ester von Fp. 131-132°C erhaltan.
Figure imgb0060
 = -5,2° (c = 0,5; Dimethylformamaid). Für C40H38ClN3O9
Figure imgb0061
Figure imgb0059
 A suspension of 0.005 mol of phenylalanyl tyrosine methyl ester trifluoroacetate in 15 ml absolute dimethylformamide is initially mixed with stirring at 0 ° C. with 0.005 mol of triethylamine and after 10 minutes with 0.005 mol of ACE-2,4,5-trichlorophenyl ester. After stirring for two hours, finally at room temperature, the reaction mixture is mixed with 150 ml of water, extracted three times with xthylacetate and the organic phase is extracted three times with nHCl solution. The solution is then washed neutral with water, dried over Na 2 SO 4 and evaporated. After recrystallization from acetone / petroleum ether, 84% of theory of N-ACE-phenylalanyl tyrosine methyl ester of mp 131-132 ° C. is obtained.
Figure imgb0060
 = -5.2 ° (c = 0.5; dimethylformamaid). For C 40 H 38 ClN 3 O 9
Figure imgb0061

B e i s Die 1 20B e i s Die 1 20 ACE-GlycylalanylphenylalninmethylesterACE-Glycylalanylphenylalninmethylester

Figure imgb0062
analog Beispiel 19 mit Glycylalanylphenylalaninmethylester hydrochlorid,; Fp. 145-147°C (aus Isopropanol);
Figure imgb0063
 = -7,2° (c = 0,5; Dimethylformamid); Ausbeute 83 der Theorie. Für C36H37ClN4O9
Figure imgb0064
Figure imgb0062
 analogously to Example 19 with glycylalanylphenylalanine methyl ester hydrochloride; Mp 145-147 ° C (from isopropanol);
Figure imgb0063
 = -7.2 ° (c = 0.5; dimethylformamide); Yield 83 of theory. For C 36 H 37 ClN 4 O 9
Figure imgb0064

Beispiel 21Example 21 a) Nα-Formyl-Nγ-benzyloxycarbonyldiaminobutyrylphenyl= alaninhydrazida) Nα-formyl-Nγ-benzyloxycarbonyldiaminobutyrylphenyl = alanine hydrazide

53 g (C,12 Mol) Nα-Formyl-Nγ-benzyloxycarbonyldiaminobutyryl= phenylalaninmethylester werden bei 40°C in 400 ml Methanol gelöst und mit 10 g (ca. 0,16 Mol) 80 %igen Hydrazinhydrat versetzt. Nach 24-stilndigem Stehen bei Raunterperatur wird der ausgefallene Niederschlag abgesaugt, die Mutterlauge auf 50 ml eingeengt und erneut zur Kristallisation gebracht. Fp. 205-207°C (aus wäßrigem Dimethylfornamid); Ausbeute 50 g = 94 % der Theorie;

Figure imgb0065
= -11,5° (c = 2; Dimethylformamid). Für C22H27N5O5
Figure imgb0066
 53 g (C, 12 mol) of Nα-formyl-Nγ-benzyloxycarbonyldiaminobutyryl = phenylalanine methyl ester are dissolved in 400 ml of methanol at 40 ° C. and 10 g (approx. 0.16 mol) of 80% hydrazine hydrate are added. After standing for 24 days at room temperature, the precipitate which has separated out is filtered off with suction, the mother liquor is concentrated to 50 ml and brought to crystallization again. Mp 205-207 ° C (from aqueous dimethylfornamide); Yield 50 g = 94% of theory;
Figure imgb0065
 = -11.5 ° (c = 2; dimethylformamide). For C 22 H 27 N 5 O 5
Figure imgb0066

b) Nα-Forryl-Nγ-benzyloxycarbonyldiaminobutyrylphenylahanyl= phenylalanimmethylesterb) Nα-Forryl-Nγ-benzyloxycarbonyldiaminobutyrylphenylahanyl = phenylalanimethyl

88,3 g (0,2 Mol) der vorstehend unter a) beschriebenen Verbindung we-den unter Erwärmen in 1000 ml Dimethylformamid gelöst und rit 20 nl Eisessig und 400 ml nHCl vermischt. Nach Abkühlen auf -10°C werden zunächst langsam 14,4 g (0,208 Mol) Natriumnitrit in 60 ml Wasser und anschließend eine vorgekühlte Lösung von 35,8 g (0,02 Mol) L-Phenylalanmethylester= hydrochlorid, gelöst in 200 ml Dinethylformamid, hinzugefügt. Die Peaktionslösung wird mit etwa 54 g Triäthylamin neutralgestellt und 24 8td. im Kühlschrank aufbewahrt. Nach Aufschlämmen rit doppelter Menge Wasser wird der ausgefallene Niderschlag abfiltriert, mit n Salzsäure und Wasser gewaschen, getrocknet und aus Methanol rekristallisiert. Fp. 179-181°C,

Figure imgb0067
= -22,50 (c = 2; Dimethylformamid); Ausbeute 106 g = 92 % der Theorie. Für C32H36N4O7
Figure imgb0068
 88.3 g (0.2 mol) of the compound described above under a) are dissolved in 1000 ml of dimethylformamide with heating and mixed with 20 nl of glacial acetic acid and 400 ml of nHCl. After cooling to -10 ° C., 14.4 g (0.208 mol) of sodium nitrite in 60 ml of water are slowly added first, followed by a precooled solution of 35.8 g (0.02 mol) of L-phenylalanomethyl ester = hydrochloride, dissolved in 200 ml of dinethylformamide , added. The reaction solution is neutralized with about 54 g of triethylamine and 24 8td. stored in the fridge. After slurrying with double the amount of water, the precipitated precipitate is filtered off, washed with n hydrochloric acid and water, dried and recrystallized from methanol. Mp 179-181 ° C,
Figure imgb0067
 = -22.5 0 (c = 2; dimethylformamide); Yield 106 g = 92% of theory. For C 32 H 36 N 4 O 7
Figure imgb0068

c) Nα-Benzyloxycarbonyldiaminobutyrylphenylalanylphenyl= alaninmethylesterhydrochloridc) Nα-Benzyloxycarbonyldiaminobutyrylphenylalanylphenyl = alanine methyl ester hydrochloride

52 g (0,0885 Mol) der vorstehend unter b) beschriebenen Verbindung werden in 150 ml Methanol und 35 ml n methanolischer HCl suspendiert und 20 Stunden bei Raumtemperatur gerührt. Die nunmehr klare Lösung wird eingedampft und der Rückstand aus Methanol/Äther rekristallisiert. Fp. 220-222°C, Ausbeute 29 g (= 54 % der Theorie).

Figure imgb0069
+1,65 (c = 2; Dimethylformamid) Für C31H37ClN4O6 1/2 H20
Figure imgb0070
 52 g (0.0885 mol) of the compound described above under b) are suspended in 150 ml of methanol and 35 ml of methanolic HCl and stirred for 20 hours at room temperature. The now clear solution is evaporated and the residue is recrystallized from methanol / ether. Mp 220-222 ° C, yield 29 g (= 54% of theory).
Figure imgb0069
 + 1, 65 (c = 2; dimethylformamide) for C 31 H 37 ClN 4 O 6 1/2 H 2 0
Figure imgb0070

d) Nα-ACE-Nγ-Benznloxvcarbonyldiaminobutyrylphenylalany1= phenylalaninmethylesterd) Nα-ACE-Nγ-Benznloxvcarbonyldiaminobutyrylphenylalany1 = phenylalanine methyl ester

Figure imgb0071
analog Beispiel 19 aus vorstehend unter c) beschriebener Verbindung und ACE-2,4,5-Trichlorphenylester. Fp. 22u-227°C (aus Dioxan/Äther 2:1); Ausbeute 69 % d.Th.
Figure imgb0072
 = -20,6 (c = 0,5; Dimtthylformamid) Für C52H52ClN5O11
Figure imgb0073
Figure imgb0071
 analogously to Example 19 from the compound described above under c) and ACE-2,4,5-trichlorophenyl ester. Mp 22u-227 ° C (from dioxane / ether 2: 1); Yield 69% of theory
Figure imgb0072
 = -20.6 (c = 0.5; dimethylformamide) For C 52 H 52 ClN 5 O 11
Figure imgb0073

Claims (5)

1) Indolylacetoxyacetylaminoessigsäure-Derivate der allgemeinen Formel
Figure imgb0074
in welcher m und n für die Ziffern O oder 1 stehen, X für eine -NH- oder -OCH2-Gruppe steht, R1,R2 und R3 gleich oder verschieden sein können und für ein Wasserstoffatom, eine gegebenenfalls substituierte Alkylgruppe, eine gegebenenfalls substituierte Arylgruppe, eine gegebenenfalls substituierte Aralkylgruppe, eine gegebenenfalls substituierte Heterocyclusmethylgruppe mit 1 oder 2 Ringen und mit je 5, 6 oder 7 Ringgliedern, in denen 1 oder 2 Glieder durch Heteroatome ersetzt sein können, und für den Fall, daß m und n für die Ziffer O stehen, R1 für eine Aminogruppe, eine Alkoxycarbonylgruppe oder eine Aralkoxycarbonylgruppe steht, R4 für eine Hydroxygruppe oder für eine gegebenenfalls, substituierte Alkoxygruppe, eine gegebenenfalls substituierte Aralkoxygruppe, eine Aminogruppe oder eine gegebenenfalls substituierte Alkylaminogruppe, eine gegebenenfalls substituierte Aralkylaminogruppe, eine gegebenenfalls substituierte Arylaminogruppe steht,
sowie deren gegebenenfalls mit Säuren und Basen gebildeten physiologisch verträglichen Salze. 1) Indolylacetoxyacetylaminoacetic acid derivatives of the general formula
Figure imgb0074
 in which m and n stand for the digits O or 1, X represents an -NH or -OCH 2 group, R 1 , R 2 and R 3 may be the same or different and represent a hydrogen atom, an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted aralkyl group, an optionally substituted heterocycle methyl group with 1 or 2 rings and each with 5, 6 or 7 Ring members in which 1 or 2 members can be replaced by heteroatoms, and in the event that m and n stand for the number O, R 1 for an amino group, an alkoxycarbonyl group or an aralkoxycarbonyl group, R 4 represents a hydroxyl group or an optionally substituted alkoxy group, an optionally substituted aralkoxy group, an amino group or an optionally substituted alkylamino group, an optionally substituted aralkylamino group, an optionally substituted arylamino group,
as well as their physiologically tolerable salts which may be formed with acids and bases. 2) Verfahren zur Herstellung von Indolylacetoxyacetylaminoessigsäure-Derivaten gemäß Anspruch 1, dadurch gekennzeichnet, daß man a) [1-(4-Chlorbenzoyl)-5-methöxy-2-methyl-3-indolyl]acetoxy- essigsäure (nachfolgend als ACE-OH bezeichnet) mit Chlorameisensäureestern der allgemeinen Formel
Figure imgb0075
in weicher R5 für eine Alkylgruppe steht, zu gemischten Anhydriden der allgemeinen Formel
Figure imgb0076
 in welcher R5 die oben angegebene Bedeutung hat, umsetzt und diese mit Verbindungen der allgemeinen Formel
Figure imgb0077
in welcher m, n, R1 bis R4 die oben angeführte Bedeutung haben, zur Reaktion bringt
oder b) die Verbindung ACE-OH mit einem entsprechend substituierten Phenol zu einem aktivierten Ester der allgemeinen Formel
Figure imgb0078
in welcher Y für 2 bis 5 Halogenatome, 1 bis 2 Nitrogruppen oder für mehrere andere Elektronen-anziehende Gruppen steht,
kondensiert und mit Verbindungen der allgemeinen Formel (IV), in welcher m, n, R1 bis R4 die oben angeführte Bedeutung haben, umsetzt
oder c) für den Fall, daß Hydroxylgruppen enthaltende Aminosäurederivate esterartig verknüpft werden sollen, die Verbindung ACE-OH mit Verbindungen der allgemeinen Formel
Figure imgb0079
in welcher R4 die oben angeführte Bedeutung hat und RE für eine in der Peptidchemie übliche Aminoschutzgruppe, beispielsweise für eine Alkoxycarbonyl-oder eine Aralkoxycarbonylgruppe steht, umsetzt und anschließend den Rest R4 in bekannter Weise abspaltet
und gegebenenfalls die so erhaltenen Verbindungen der allgemeinen Formel (I) mit Säuren und Basen in die physiologisch verträglichen Salze verwandelt.2) Process for the preparation of indolylacetoxyacetylaminoacetic acid derivatives according to claim 1, characterized in that a) [1- (4-Chlorobenzoyl) -5-methoxy-2-methyl-3-indolyl] acetoxyacetic acid (hereinafter referred to as ACE-OH) with chloroformic acid esters of the general formula
Figure imgb0075
 in softer R 5 represents an alkyl group, to mixed anhydrides of the general formula
Figure imgb0076
 in which R 5 has the meaning given above, and this with compounds of the general formula
Figure imgb0077
 in which m, n, R 1 to R 4 have the meaning given above, brings about the reaction
or b) the compound ACE-OH with a correspondingly substituted phenol to an activated ester of the general formula
Figure imgb0078
 in which Y represents 2 to 5 halogen atoms, 1 to 2 nitro groups or for several other electron-attracting groups,
condensed and reacted with compounds of the general formula (IV) in which m, n, R 1 to R 4 have the meaning given above
or c) in the event that amino acid derivatives containing hydroxyl groups are to be linked in an ester-like manner, the compound ACE-OH with compounds of the general formula
Figure imgb0079
 in which R 4 has the meaning given above and R E represents an amino protective group which is customary in peptide chemistry, for example an alkoxycarbonyl or an aralkoxycarbonyl group, and then cleaves off the radical R 4 in a known manner
and optionally the compounds of the general formula (I) thus obtained are converted into the physiologically tolerable salts with acids and bases. 3) Arzneimittel enthaltend mindestens ein Indolylacetoxyacetylaminoessigsäure-Derivat gemäß Anspruch 1.3) Medicament containing at least one indolylacetoxyacetylaminoacetic acid derivative according to claim 1. 4) Verfahren zur Herstellung von Arzneimitteln, dadurch gekennzeichnet, daß man Indolylacetoxyacetylaminoessigsäure-Derivate gemäß Anspruch 1 mit inerten nicht toxischen, pharmazeutisch geeigneten Trägerstoffen vermischt.4) Process for the preparation of medicaments, characterized in that indolylacetoxyacetylaminoacetic acid derivatives according to claim 1 are mixed with inert, non-toxic, pharmaceutically suitable excipients. 5) Verwendung von Indolylacetoxyacetylaminoessigsäure-Derivaten zur Behandlung von Entzündungen und rheumatischen Erkrankungen.5) Use of indolylacetoxyacetylaminoacetic acid derivatives for the treatment of inflammation and rheumatic diseases.
EP78100523A 1977-08-06 1978-07-27 Indolacetoxyacetylaminoacid derivatives, process for their preparation and their use in drugs Expired EP0000741B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19772735537 DE2735537A1 (en) 1977-08-06 1977-08-06 INDOLACETOXYACETYLAMINO ACID DERIVATIVES, METHOD FOR THEIR MANUFACTURING AND USE AS A MEDICINAL PRODUCT
DE2735537 1977-08-06

Publications (3)

Publication Number Publication Date
EP0000741A2 true EP0000741A2 (en) 1979-02-21
EP0000741A3 EP0000741A3 (en) 1979-03-07
EP0000741B1 EP0000741B1 (en) 1981-07-22

Family

ID=6015810

Family Applications (1)

Application Number Title Priority Date Filing Date
EP78100523A Expired EP0000741B1 (en) 1977-08-06 1978-07-27 Indolacetoxyacetylaminoacid derivatives, process for their preparation and their use in drugs

Country Status (4)

Country Link
EP (1) EP0000741B1 (en)
JP (1) JPS5430160A (en)
DE (2) DE2735537A1 (en)
IT (1) IT7826537A0 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0047358A1 (en) * 1980-09-10 1982-03-17 A. Nattermann & Cie. GmbH Indol acetic derivatives, process for producing the same and pharmaceutical compositions comprising the same
EP0382854A1 (en) * 1988-07-05 1990-08-22 Zeria Pharmaceutical Co., Ltd. Indoleacetic acid derivatives, process for their preparation, and medicines containing same as active ingredients
US7718161B2 (en) 2004-06-09 2010-05-18 Ucb Pharma Gmbh Method for treating a motoneuron disorder

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3206885A1 (en) * 1982-02-26 1983-09-15 Troponwerke GmbH & Co KG, 5000 Köln INDOLDER DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS
DE3206887A1 (en) * 1982-02-26 1983-09-15 Troponwerke GmbH & Co KG, 5000 Köln METHOD FOR THE PRODUCTION OF 1- (4-CHLOROBENZOYL) -5-METHOXY-2-METHYL-3-INDOLACETOXYACETIC ACID
JPS59204172A (en) * 1983-04-28 1984-11-19 Kowa Co Preparation of acemetacin
JPH0417306Y2 (en) * 1984-12-26 1992-04-17
US6762182B1 (en) 1999-01-07 2004-07-13 Vanderbilt University Converting cox inhibition compounds that are not COX-2 selective inhibitors to derivatives that are COX-2 selective inhibitors
US6207700B1 (en) 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
US6306890B1 (en) 1999-08-30 2001-10-23 Vanderbilt University Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors
JP2007534702A (en) 2004-04-26 2007-11-29 バンダービルト・ユニバーシティ Indoleacetic acid and indeneacetic acid derivatives as therapeutic agents with low gastrointestinal toxicity
CN101528222A (en) 2006-06-19 2009-09-09 范德比尔特大学 Methods and compositions for diagnostic and therapeutic targeting of COX-2
WO2013059245A1 (en) 2011-10-17 2013-04-25 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2192828A1 (en) * 1972-07-14 1974-02-15 Troponwerke Dinklage & Co
DE2413125A1 (en) * 1974-03-15 1975-10-09 Schering Ag INDOLYLACETYLAMINO ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PREPARATIONS CONTAINING THESE COMPOUNDS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2192828A1 (en) * 1972-07-14 1974-02-15 Troponwerke Dinklage & Co
DE2413125A1 (en) * 1974-03-15 1975-10-09 Schering Ag INDOLYLACETYLAMINO ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PREPARATIONS CONTAINING THESE COMPOUNDS

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0047358A1 (en) * 1980-09-10 1982-03-17 A. Nattermann & Cie. GmbH Indol acetic derivatives, process for producing the same and pharmaceutical compositions comprising the same
EP0382854A1 (en) * 1988-07-05 1990-08-22 Zeria Pharmaceutical Co., Ltd. Indoleacetic acid derivatives, process for their preparation, and medicines containing same as active ingredients
EP0382854A4 (en) * 1988-07-05 1991-11-13 Zeria Pharmaceutical Co., Ltd. Indoleacetic acid derivatives, process for their preparation, and medicines containing same as active ingredients
US5177223A (en) * 1988-07-05 1993-01-05 Zeria Pharmaceutical Co., Ltd. Indoleacetic acid derivatives, process for their preparation, and medicines containing same as active ingredients
US7718161B2 (en) 2004-06-09 2010-05-18 Ucb Pharma Gmbh Method for treating a motoneuron disorder

Also Published As

Publication number Publication date
DE2860858D1 (en) 1981-10-29
EP0000741B1 (en) 1981-07-22
DE2735537A1 (en) 1979-02-22
IT7826537A0 (en) 1978-08-04
JPS5430160A (en) 1979-03-06
EP0000741A3 (en) 1979-03-07

Similar Documents

Publication Publication Date Title
DE2366070C2 (en)
EP0012361B1 (en) Amino-pyrimidine-carbanilides, process for their preparation, medicines containing them
EP0242851A1 (en) N-(2'-aminophenyl)-benzamide derivatives, process for their manufacture and their application in the treatment of neoplastic illness
EP0000741B1 (en) Indolacetoxyacetylaminoacid derivatives, process for their preparation and their use in drugs
DE3005580C2 (en)
DE2856753A1 (en) N-SUBSTITUTED OMEGA -AMINOALKANOYL- OMEGA -AMINOALKANIC ACIDS, THEIR USE AND METHOD FOR THE PRODUCTION THEREOF, AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
EP0028765A1 (en) Alkyl-urea derivatives for the treatment of lipometabolic diseases; process for their preparation, their use in medicaments for the treatment of lipometabolic disorders, medicaments containing them, process for the preparation of the medicaments, and some alkyl-urea derivatives
DE3247615A1 (en) SUBSTITUTED PHENYLSULFONYLOXYBENZIMIDAZOLE CARBAMINATES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT
DE2012138B2 (en) N SQUARE BRACKETS TO 4-(BETA-PYRAZINE- 2-CARBOXYAMIDO-AETHYL)-BENZENESULPHONYL SQUARE BRACKETS TO -N'-CYCLOALKYL UREAS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
DE1445675C3 (en) Pyridylureas and process for their preparation
DE2446758A1 (en) NEW 2,6-DISUBSTITUTED 2-PHENYLIMINO-IMIDAZOLIDINE, THEIR ACID-ADDITIONAL SALTS, THESE MEDICINAL PRODUCTS AND THE PROCESS FOR THEIR PRODUCTION
EP0665228A1 (en) Pharmaceutical compositions containing 3-phenylsulfonyl-3,7-diazabicyclo 3,3,1 nonanes
DE3447003A1 (en) 7-ACYLAMINO-9A-METHOXYMITOSANE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS
EP0271099A2 (en) Substituted aminopropionic acid amides, process for their preparation, agents containing them and their use as well as the intermediates formed during the preparation
DE1620747C3 (en) Carbothiamine and its non-toxic organic or inorganic acid addition salts and processes for the preparation of these compounds
EP0083729A1 (en) Substituted 1-benzoyl-2-phenylimino-imidazolidines, their acid addition salts, process for their preparation and pharmaceutical compositions containing them
AT304471B (en) Process for the preparation of new 1-sec.amino-2-hydroxy-3 - [(p-alkenyloxy- or p-alkinyloxy) -phenoxy] propanes and their acid addition salts
DE3704404A1 (en) LIQUID AMID DERIVATIVES
EP0150719B1 (en) Substituted salicylamides, process for their production and their use as pharmaceutical preparations
DE2200648A1 (en) Process for the preparation of monosubstituted 1-carbamoyl-2-benzimidazolyl carbamates
DE1795423C3 (en) Pivaloyloxymethyl alpha-aminobenzyl penicillinate
DE2253554A1 (en) 2-AMINO-2-OXAZOLINE AND THE PROCESS FOR THEIR PRODUCTION
EP0029983A1 (en) Benzenesulfonyl ureas, processes for their preparation and pharmaceutical compositions containing these compounds
DE2031360A1 (en) New cyclic compounds and processes for their preparation
DE3229453C2 (en)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

17P Request for examination filed
AK Designated contracting states

Designated state(s): BE CH DE FR GB NL

17P Request for examination filed
AK Designated contracting states

Designated state(s): BE CH DE FR GB NL

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19810630

Year of fee payment: 4

AK Designated contracting states

Designated state(s): BE CH DE FR GB NL

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19810731

Year of fee payment: 4

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19810930

Year of fee payment: 4

Ref country code: CH

Payment date: 19810930

Year of fee payment: 4

Ref country code: BE

Payment date: 19810930

Year of fee payment: 4

REF Corresponds to:

Ref document number: 2860858

Country of ref document: DE

Date of ref document: 19811029

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Effective date: 19820731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19830127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19830201

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19830331

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19830401

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

GBPC Gb: european patent ceased through non-payment of renewal fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19881117

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT